Antares Pharma (NASDAQ:ATRS) Stock Price Down 7.1%


Share on StockTwits

Antares Pharma, Inc. (NASDAQ:ATRS)’s share price traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $4.38 and last traded at $4.44. 2,747,716 shares changed hands during trading, an increase of 101% from the average session volume of 1,369,723 shares. The stock had previously closed at $4.78.

Several research analysts recently issued reports on the company. TheStreet upgraded Antares Pharma from a “c” rating to a “b-” rating in a research report on Wednesday, November 25th. Zacks Investment Research downgraded Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $5.15.

The stock has a market capitalization of $740.02 million, a PE ratio of 79.68 and a beta of 1.44. The company has a current ratio of 2.47, a quick ratio of 2.08 and a debt-to-equity ratio of 0.53. The company’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $3.41.

In other Antares Pharma news, EVP Peter J. Graham sold 45,000 shares of Antares Pharma stock in a transaction that occurred on Thursday, February 18th. The shares were sold at an average price of $4.93, for a total value of $221,850.00. Following the completion of the sale, the executive vice president now directly owns 582,490 shares of the company’s stock, valued at approximately $2,871,675.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas J. Garrity sold 70,000 shares of Antares Pharma stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $4.06, for a total transaction of $284,200.00. Following the completion of the sale, the director now directly owns 244,406 shares of the company’s stock, valued at $992,288.36. The disclosure for this sale can be found here. Insiders sold a total of 713,133 shares of company stock valued at $3,468,268 over the last ninety days. 5.90% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership grew its stake in shares of Antares Pharma by 10.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 485,133 shares of the specialty pharmaceutical company’s stock valued at $1,310,000 after buying an additional 45,120 shares during the period. Stonepine Capital Management LLC purchased a new stake in shares of Antares Pharma during the 3rd quarter valued at $3,255,000. IndexIQ Advisors LLC grew its stake in shares of Antares Pharma by 11.5% during the 4th quarter. IndexIQ Advisors LLC now owns 88,748 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 9,163 shares during the period. Mackay Shields LLC purchased a new stake in shares of Antares Pharma during the 3rd quarter valued at $595,000. Finally, HealthInvest Partners AB purchased a new stake in shares of Antares Pharma during the 4th quarter valued at $6,863,000. 39.92% of the stock is owned by institutional investors.

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: What is an economic bubble?

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.